T78.40 is a clinical code used for the diagnosis of hypersensitivity reactions where the specific allergen, the clinical manifestation (such as allergic rhinitis or dermatitis), or the underlying physiological mechanism is not documented or known at the time of encounter. This code represents a systemic or localized overreaction of the immune system to an external substance that is typically benign to non-atopic individuals. It is often utilized in acute settings when a patient presents with classic signs of an allergic reaction—such as hives or swelling—but the direct trigger remains idiopathic or undetermined. In clinical practice, T78.40 serves as a general classification for allergic states, including hypersensitivity not otherwise specified (NOS) and clinical reactions to unspecified environmental, medicinal, or biological agents.
Avoid using unspecified codes whenever possible by identifying the specific allergen or route of exposure.
Example: Patient presents with diffuse urticaria and pruritus after self-administering an over-the-counter herbal supplement. Patient is also a known asthmatic (J45.909), which increases the complexity of management. Initial encounter for acute allergic reaction to unknown component of supplement. Billing focus: Use T78.40XA for initial encounter. Risk adjustment: Asthmatic comorbidity increases clinical severity and monitoring requirements.
Billing Focus: The 7th character A (initial) must be used for the first encounter of this acute condition.
Document the absence of systemic symptoms to differentiate from anaphylaxis.
Example: Patient evaluated for localized hives on the torso and neck. Onset 2 hours ago. Negative for shortness of breath, tongue swelling, or hypotension. Current symptoms: localized erythema and itching. Billing focus: Documenting negative findings justifies the use of T78.40 rather than the more severe T78.2 (Anaphylactic shock). Risk adjustment: Demonstrates low immediate acuity but requires follow-up to prevent future exacerbations.
Billing Focus: Clear documentation of the absence of shock or respiratory distress supports T78.40 over higher-level emergency codes.
Specify the encounter type (initial, subsequent, or sequela) to ensure accurate 7th character application.
Example: Patient returning for follow-up of allergic rash first evaluated 4 days ago. Rash is fading; no new lesions. Continuing cetirizine. Billing focus: Code as T78.40XD (subsequent encounter). Risk adjustment: Subsequent care for injury/reaction codes tracks the episode of care and resource utilization.
Billing Focus: Required use of 7th character D for subsequent care of the reaction.
Include all comorbid allergic conditions such as rhinitis or dermatitis to paint a complete clinical picture.
Example: Patient with chronic allergic rhinitis (J30.9) presents with an acute, unspecified allergic flare characterized by generalized itching and sneezing. Unknown environmental trigger. Billing focus: Reporting both the acute (T78.40XA) and chronic (J30.9) conditions. Risk adjustment: Comorbid chronic allergies increase the risk of severe future reactions and higher medical decision making.
Billing Focus: Concurrent coding of chronic allergic rhinitis supports the medical necessity for allergy testing.
Document the specific manifestations of the allergy, such as urticaria or edema.
Example: Patient presents with acute onset of angioedema (T78.3XXA) and generalized urticaria. Cause is currently unknown. Billing focus: Specify the manifestations (angioedema) along with the unspecified allergy code. Risk adjustment: Angioedema is a more severe manifestation than simple pruritus and impacts the patient's risk profile significantly.
Billing Focus: Manifestation codes (like L50.0) should be sequenced according to official guidelines.
Appropriate for a straightforward follow-up on a stable allergic reaction or a mild initial presentation requiring low-level management.
Used when the patient has a complex history, comorbidities like asthma, or requires more extensive evaluation of the reaction.
Initial evaluation of a new patient presenting with a simple allergic reaction.
Comprehensive initial evaluation of a new patient with a potentially severe reaction or significant history.
Standard procedure used to identify the specific allergen when a patient presents with an unspecified allergy.
Follow-up testing if percutaneous tests are negative but clinical suspicion remains high.
Part of a long-term treatment plan once the specific cause of the 'unspecified' allergy is identified.
Common for patients undergoing immunotherapy for multiple suspected allergens.
Used for immediate treatment of an acute allergic reaction with epinephrine or antihistamines.
Required if the unspecified allergy causes bronchospasm or respiratory symptoms.